10x Genomics (TXG) Income from Continuing Operations (2018 - 2026)

10x Genomics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting -$17.9 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 151.92% year-over-year to -$17.9 million; the TTM figure through Jun 2026 stood at -$75.1 million (up 11.2% YoY), while the FY2025 annual figure was -$43.5 million, up 76.16% from the prior year.
• Income from Continuing Operations came in at -$17.9 million for Q2 2026 at 10x Genomics, down from -$13.5 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $34.5 million in Q2 2025 to a low of -$93.0 million in Q3 2023.
• Average Income from Continuing Operations over 5 years is -$37.7 million, with a median of -$39.9 million recorded in 2022.
• Year-over-year, Income from Continuing Operations plunged 483.22% in 2022 and soared 191.14% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$17.2 million in 2022, then sank by 184.36% to -$49.0 million in 2023, then dropped by 0.16% to -$49.0 million in 2024, then surged by 66.85% to -$16.3 million in 2025, then declined by 10.33% to -$17.9 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$17.9 million in Q2 2026, -$13.5 million in Q1 2026, and -$16.3 million in Q4 2025.